Interleukins in the control of osteoclast differentiation

被引:86
作者
Martin, TJ [1 ]
Romas, E [1 ]
Gillespie, MT [1 ]
机构
[1] St Vincents Inst Med Res, Fitzroy, Vic 3065, Australia
来源
CRITICAL REVIEWS IN EUKARYOTIC GENE EXPRESSION | 1998年 / 8卷 / 02期
关键词
glycoprotein; 130; interleukin-11; interleukin-18; osteoprotegerin; osteoclast differentiating factor; TRANCE;
D O I
10.1615/CritRevEukarGeneExpr.v8.i2.10
中图分类号
Q81 [生物工程学(生物技术)]; Q93 [微生物学];
学科分类号
071005 ; 0836 ; 090102 ; 100705 ;
摘要
To maintain homeostasis of bone, the production of osteoblasts and osteoclasts is tightly regulated. At the local level, hormones and cytokines control formation of osteoclasts from hemopoietic precursors by acting upon osteoblastic-stromal cells and in some cases also upon cells of the immune system. Osteoblasts regulate osteoclast formation by providing physical support and cytokines such as M-CSF and IL-11, which promote osteoclast differentiation. Osteoblasts are also a source of IL-18, which limits osteoclast formation. The require ment of contact between osteoblasts and hemopoietic cells for successful osteoclast formation led to a concept of a membrane-anchored stromal cell molecule that programs osteoclast differentiation. This mechanism has been highlighted by the discovery of osteoprotegerin (OPG), a soluble tumor necrosis factor (TNF) family member that inhibits osteoclast formation. The ligand for OPG is a novel transmembrane TNF receptor superfamily member, the osteoclast differentiating factor (ODF). The recognition of the osteoprotegerin/osteoprotegerin-ligand axis will lead to new insights into the control of osteoclast differentiation by interleukins.
引用
收藏
页码:107 / 123
页数:17
相关论文
共 144 条
  • [1] Cytokines and T-lymphocyte subsets in healthy post-menopausal women: Estrogen retards bone loss without affecting the release of IL-1 or IL-1ra
    Abrahamsen, B
    Bendtzen, K
    BeckNielsen, H
    [J]. BONE, 1997, 20 (03) : 251 - 258
  • [2] AKATSU T, 1991, J BONE MINER RES, V6, P183
  • [3] ALHUMIDAN A, 1991, J BONE MINER RES, V6, P3
  • [4] Transgenic mice expressing soluble tumor necrosis factor-receptor are protected against bone loss caused by estrogen deficiency
    Ammann, P
    Rizzoli, R
    Bonjour, JP
    Bourrin, S
    Meyer, JM
    Vassalli, P
    Garcia, I
    [J]. JOURNAL OF CLINICAL INVESTIGATION, 1997, 99 (07) : 1699 - 1703
  • [5] ANDERSON DM, 1997, NATURE, V345, P175
  • [6] INHIBITION OF THE PRODUCTION AND EFFECTS OF INTERLEUKIN-1 AND TUMOR-NECROSIS-FACTOR-ALPHA IN RHEUMATOID-ARTHRITIS
    AREND, WP
    DAYER, JM
    [J]. ARTHRITIS AND RHEUMATISM, 1995, 38 (02): : 151 - 160
  • [7] ATHANASOU NA, 1988, BONE MINER, V3, P317
  • [8] CELL-MEDIATED EXTRACELLULAR ACIDIFICATION AND BONE-RESORPTION - EVIDENCE FOR A LOW PH IN RESORBING LACUNAE AND LOCALIZATION OF A 100-KD LYSOSOMAL MEMBRANE-PROTEIN AT THE OSTEOCLAST RUFFLED BORDER
    BARON, R
    NEFF, L
    LOUVARD, D
    COURTOY, PJ
    [J]. JOURNAL OF CELL BIOLOGY, 1985, 101 (06) : 2210 - 2222
  • [9] The tumor necrosis factor ligand and receptor families
    Bazzoni, F
    Beutler, B
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 1996, 334 (26) : 1717 - 1725
  • [10] DEMONSTRATION OF ESTROGEN AND VITAMIN-D RECEPTORS IN BONE-MARROW-DERIVED STROMAL CELLS - UP-REGULATION OF THE ESTROGEN-RECEPTOR BY 1,25-DIHYDROXYVITAMIN-D(3)
    BELLIDO, T
    GIRASOLE, G
    PASSERI, G
    YU, XP
    MOCHARLA, H
    JILKA, RL
    NOTIDES, A
    MANOLAGAS, SC
    [J]. ENDOCRINOLOGY, 1993, 133 (02) : 553 - 562